Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
none appears on more than one
Timothy J. Miller, Ph.D., age 54, is a director nominee of Research Alliance Corp. III (RACC), a special purpose acquisition company. He currently serves as Chief Executive Officer, President, and Co-Founder of Forge Biologics, a venture-backed gene therapy development engine focused on accelerating access to life-saving adeno-associated virus (AAV) gene therapies. In connection with the RACC SPAC, Miller is identified among the "Other Class B Shareholders" in a planned merger with OHB Pediatrics Ltd. (Oak Hill Bio), a transaction reported as a material event by the SPAC. He was appointed to Research Alliance's board of directors and named to multiple board committees, effective May of the relevant year.
Miller is a seasoned biotech entrepreneur with over 30 years of experience spanning business development, scientific research, product development, and clinical operations, with a particular focus on transitioning novel gene and cell therapies through pre-clinical development and Phase 3 human clinical trials. Prior to founding Forge Biologics, he co-founded Abeona Therapeutics, a rare disease gene and cell therapy company, where he served as CEO and President from 2012 through early 2018 and led the company's initial public offering in 2015. His earlier career includes roles as CEO-In-Residence at BioEnterprise, Inc.; President and CEO of Red5 Pharmaceuticals LLC; Senior Director of Product Development at SironRX Therapeutics, Inc.; Senior Scientist of Product Development at Juventas Therapeutics, Inc.; Research Associate in Molecular Biology at Copernicus Therapeutics, Inc.; and Research Associate II and Lab Manager at Case Western Reserve University. Throughout these roles, he has built expertise in gene therapy pipeline development, regulatory strategy, investor relations, M&A activities, licensing, cGMP manufacturing, and clinical development.
Miller earned his Ph.D. in Pharmacology from Case Western Reserve University and both his Bachelor of Science and Master of Science degrees in Biology/Molecular Science from John Carroll University. He is described as an avid patient-centric drug developer and entrepreneur with a proven track record of building successful gene and cell therapy companies and driving them through public markets and advanced clinical trials. His leadership at Forge Biologics has positioned the company as a significant player in the viral gene therapy contract development and manufacturing space, with operations advancing programs into Phase 3 clinical trials.
This record is keyed to SEC CIK 0001692659 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 11 institutional-holder rows on these vehicles, under 10 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.